Kala Bio Inc (NAS:KALA)

$ 6.98 0.045 (0.65%) Market Cap: 31.97 Mil Enterprise Value: 16.60 Mil PE Ratio: 0 PB Ratio: 4.68 GF Score: 44/100

KALA BIO Inc at HC Wainwright Ophthalmology Virtual Conference - Pre Recorded Transcript
Aug 16, 2023
Kala Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Q2 2022 Kala Pharmaceuticals Inc Earnings Call Transcript
Aug 11, 2022

$16.4 (-5.75%)

Earnings
Q1 2022 Kala Pharmaceuticals Inc Earnings Call Transcript
May 16, 2022

$37.08 (+8.47%)

Earnings
Q4 2021 Kala Pharmaceuticals Inc Earnings Call Transcript
Mar 29, 2022

$75 (-14.29%)

Earnings
Q3 2021 Kala Pharmaceuticals Inc Earnings Call Transcript
Nov 15, 2021

$105 (+1.45%)

Earnings
Q2 2021 Kala Pharmaceuticals Inc Earnings Call Transcript
Aug 05, 2021

$159 (-5.07%)

Earnings
Kala Pharmaceuticals Inc at BofA Securities 2021 Healthcare Conference (Virtual) Transcript
May 13, 2021
Q1 2021 Kala Pharmaceuticals Inc Earnings Call Transcript
May 05, 2021

$297.5 (-7.75%)

Earnings
Q4 2020 Kala Pharmaceuticals Inc Earnings Call Transcript
Feb 25, 2021

$386.75 (-13.38%)

Earnings
Kala Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2021
Q3 2020 Kala Pharmaceuticals Inc Earnings Call Transcript
Nov 05, 2020

$363 (+0.14%)

Earnings
Kala Pharmaceuticals, Inc. - Special Call Transcript
Oct 27, 2020
Kala Pharmaceuticals, Inc. - Special Call Transcript
Sep 17, 2020
Q2 2020 Kala Pharmaceuticals Inc Earnings Call Transcript
Aug 06, 2020

$458.5

Earnings
Kala Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 25, 2020
Kala Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 13, 2020
Q1 2020 Kala Pharmaceuticals Inc Earnings Call Transcript
May 07, 2020

$592.5 (+1.98%)

Earnings
Kala Pharmaceuticals Inc STRIDE 3 Data Conference Call Transcript
Mar 09, 2020
Q4 2019 Kala Pharmaceuticals Inc Earnings Call Transcript
Feb 12, 2020

$313.5 (-1.95%)

Earnings
Kala Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 15, 2020
Q3 2019 Kala Pharmaceuticals Inc Earnings Call Transcript
Nov 07, 2019

$185.5 (-3.39%)

Earnings
Q2 2019 Kala Pharmaceuticals Inc Earnings Call Transcript
Aug 06, 2019

$219 (-13.27%)

Earnings
Kala Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference Transcript
May 14, 2019
Q1 2019 Kala Pharmaceuticals Inc Earnings Call Transcript
May 09, 2019

$347 (-2.25%)

Earnings
Q4 2018 Kala Pharmaceuticals Inc Earnings Call Transcript
Mar 11, 2019

Earnings

Kala Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 13, 2020 / 08:20PM GMT

Release Date Price: $600.5 (+0.50%)

Transcript 10-Q8-K

William Maughan

Good afternoon. This is Bill Maughan. I'm an associate on the SMid-cap Biotech Research Team here at Bank of America. And it's my pleasure to introduce our next presenter, Mark Iwicki, CEO of Kala Pharmaceuticals. Mark?

Mark T. Iwicki

Kala Pharmaceuticals, Inc. - Chairman, President & CEO

Thank you very much. And hello, everyone. I'm the CEO of Kala and I want to thank you for joining the call this afternoon. Before getting started, I want to let everyone know that we will make forward-looking statements and all information in this presentation is as of May 13, 2020, and should not be considered current after such date.

So just moving to Slide 3, Kala was formed about 10 years ago based on our AMPPLIFY technology that lets us enhance delivery to target tissues in the eye. We have IP protection for the AMPPLIFY technology and products through at least 2033. Our product that we will spend a lot of time talking about today is EYSUVIS and that is our dry eye product that has the potential to become the preferred first line prescription

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.